Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) will look for acquisitions. Joseph Ciaffoni, Chief Executive Officer said "Our business development strategy is to diversify the organization in one or more of the following ways: diversifying within pain through commercial stage high-synergy acquisitions, diversifying beyond pain through commercial stage lower-synergy acquisitions, and diversifying into non-opioid pain solutions through the acquisition of late-stage development assets defined as Phase II or later that have the potential to generate revenue in the 2025 to 2027 time frame".